Weight & Metabolic
Does Resistance Training Protect Muscle During GLP-1 Weight Loss?
The short answer
The only completed randomized trial to combine supervised exercise with a GLP-1 drug found the combination cut body-fat percentage roughly twice as much as either liraglutide or exercise alone (-3.9 vs -1.9 vs -1.7 percentage points), and cut post-treatment weight regain by 6 kg compared with the drug alone. But that trial tested general supervised exercise, not resistance training specifically — no completed randomized trial has isolated resistance training's effect on muscle during semaglutide or tirzepatide therapy. A dedicated trial designed to answer that exact question is enrolling now, with results not yet available.
Quick answers
- What is it?
- Whether resistance training protects muscle during GLP-1-driven weight loss.
- Why are people interested in it?
- People losing significant weight on semaglutide or tirzepatide worry about losing muscle along with fat, and want to know if lifting weights prevents that.
- What has actually been studied?
- The S-LITE trial, a Copenhagen randomized trial testing supervised exercise, liraglutide, both combined, or placebo in 195 adults with obesity, plus a 2026 meta-analysis of 20 trials, 15,782 participants, on body composition with GLP-1 drugs.
- How strong is the evidence?
- The only completed randomized trial combining exercise and a GLP-1 drug found real added benefit from combining them, but it tested general supervised exercise, not resistance training specifically — no completed trial has isolated resistance training's effect during these drugs.
- What don't we know yet?
- Whether resistance training specifically, not general exercise, changes lean mass outcomes, whether preserving lean mass translates into preserved strength or function, and what happens beyond one year off treatment.
- Where can I read the original research?
- Sources at the bottom of this page: Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (S-LITE) and Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment.
The short answer: The only completed randomized trial that put supervised exercise and a GLP-1 drug in the same design — liraglutide, exercise, both combined, or placebo — found the combination roughly doubled the drop in body-fat percentage compared with either strategy alone, and cut post-treatment weight regain substantially. But "exercise" in that trial was a general supervised program, not a resistance-training arm tested on its own. Nobody has yet run a completed randomized trial isolating resistance training's effect on muscle during semaglutide or tirzepatide therapy. One is enrolling now.
What the research shows
The one trial that actually tested exercise alongside a GLP-1 drug
In a Copenhagen-based randomized, placebo-controlled trial (the S-LITE trial), 195 adults with obesity first completed an 8-week low-calorie diet, losing an average of 13.1 kg. They were then randomly assigned to one year of either a supervised exercise program, once-daily liraglutide (3.0 mg), the two combined, or placebo.
At one year, every active strategy beat placebo on weight loss: exercise alone added 4.1 kg more loss, liraglutide alone added 6.8 kg, and the combination added 9.5 kg. But the body-composition finding is the more relevant one here — the combination group's body-fat percentage dropped 3.9 percentage points, compared with 1.7 points in the exercise-only group and 1.9 points in the liraglutide-only group. In other words, adding exercise to the drug (or the drug to exercise) produced roughly double the fat-percentage improvement of either alone.
The trial describes the exercise arm only as a "moderate-to-vigorous-intensity exercise program" — it was not designed as a resistance-training-specific intervention, and the published results don't isolate strength training as its own comparison arm. That's an important limit on how far this trial can answer the specific question of resistance training.
A follow-up study tracked 109 of the original participants one year after all treatment stopped. People who had previously received the combination treatment kept 5.1 kg more weight off and 2.3 percentage points more fat-percentage improvement than those who'd had liraglutide alone. During the year off treatment, weight regain was 6.0 kg larger after stopping liraglutide alone than after stopping supervised exercise alone — and people who'd done supervised exercise (with or without the drug) were far more likely to still be down at least 10% of their original body weight a year after everything stopped.
What happens to lean mass with incretin drugs, and does resistance training change the picture
A 2026 meta-analysis pooled 20 randomized trials (15,782 participants) measuring body composition on semaglutide, tirzepatide, liraglutide, or lifestyle interventions. Lean mass made up 35.2% of total weight loss with semaglutide, 25.4% with tirzepatide, and 26.8% with liraglutide — figures the authors found were not meaningfully different from lifestyle-only weight loss (26.2%). The one group that stood apart: trials of lifestyle programs that specifically included resistance training, where lean mass made up only 17.5% of weight lost — the most favorable ratio of any group in the analysis.
That's a real signal, but it isn't a randomized comparison of resistance training added to a GLP-1 drug. It's a comparison across separate trials, of separate populations, using separate interventions. The "17.5%" group never took semaglutide or tirzepatide at all.
A widely cited narrative review on this topic estimated that incretin therapy causes roughly 10% (about 6 kg) lean mass loss on average — comparable, the authors wrote, to a decade or more of normal aging — and noted that supervised resistance training programs lasting more than 10 weeks typically produce around 3 kg of lean mass gain and 25% strength gains in general populations. Again, this is evidence borrowed from resistance-training research done outside the context of GLP-1 drugs, applied by inference.
The trial built to answer this directly — still running
A randomized controlled trial protocol published in 2026 (registered as NCT06885736, enrolling 232 adults in Kuwait) is designed to test exactly this question. Participants starting semaglutide or tirzepatide are being randomized to control, resistance exercise, protein supplementation (1.6 g/kg/day), or both, with MRI-measured quadriceps cross-sectional area as the primary outcome at 6 months. As of this writing, it has not reported results.
What a few individual cases suggest
A case series describing three patients who combined resistance training (3-5 days/week) with protein intake of 1.6-2.3 g/kg of fat-free mass while on semaglutide or tirzepatide found mixed but notable results: one patient lost 8.7% of total weight as lean soft tissue despite losing 33% of body weight overall, while the other two actually gained lean soft tissue (+2.5% and +5.8%) while losing 27% and 13% of body weight, respectively. Three people is not evidence of a population-level effect — but it demonstrates the outcome is at least physiologically possible.
What we don't know yet
Whether resistance training specifically — not general exercise — changes lean mass outcomes during GLP-1 or GIP-based therapy. The only completed randomized trial combining exercise and a GLP-1 drug used a general supervised program, not an isolated resistance-training arm.
Whether preserving lean mass translates into preserved strength or function. No trial to date has reported grip strength, gait speed, or functional testing as an outcome alongside body composition in this population.
What happens beyond one year off treatment. The only post-treatment data available extends to one year after stopping; nothing is known about longer-term trajectories with or without a resistance-training component.
What dose, frequency, or timing of resistance training works best in this specific population. General resistance-training literature offers estimates, but none of it was tested in people simultaneously suppressing appetite with a GLP-1 or GIP drug.
Whether results differ by age, sex, or baseline muscle mass. Older adults and people with sarcopenic obesity are the population of greatest clinical concern, and no trial has been powered to answer this for them specifically.
Sources
- Lundgren JR, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 2021;384(18):1719-1730. DOI
- Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. EClinicalMedicine, 2024;69:102475. DOI
- Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care, 2024;47(10):1718-1730. DOI
- Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity & Metabolism, 2026;28(6):4818-4827. DOI
- Alawadhi AA, et al. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open, 2026;16(4):e116911. DOI
- Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports, 2025;13:2050313X251388724. DOI
- Zeigler Z, et al. Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance. Healthcare, 2026;14(15):2345. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism · Energy & Performance | Evidence Index: semaglutide · tirzepatide · liraglutide
Sources
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (S-LITE)
- New England Journal of Medicine, 2021 · n=195 · DOI
- Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment
- EClinicalMedicine, 2024 · n=109 · DOI
- Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
- Diabetes Care, 2024 · DOI
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis
- Diabetes, Obesity & Metabolism, 2026 · n=15782 · DOI
- LEAN-PREP study protocol
- BMJ Open, 2026 · n=232 · DOI
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series
- SAGE Open Medical Case Reports, 2025 · n=3 · DOI
- Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation
- Healthcare, 2026 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.